ESR1 and breast neoplasm: About 70% of the breast tumors diagnosed are estrogen receptor (ER)-positive and depend on estrogens and the interactions with their ER to grow and survive; their therapeutic treatment has a good clinical prognosis and effectiveness, but antitumoral treatment resistances and undesirable side effects (ovarian cysts, endometrial cancer, or blood clots) remain clinically challenging.